omniture
东曜药业有限公司 BioDlink Biopharm Co., Ltd.

Latest News

BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough

* Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first appro...

2025-11-28 21:00 623

BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC

* Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG...

2025-11-21 21:00 1238

BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC

* BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating rec...

2025-11-05 21:00 1014

BioDlink Completes First International Shipment of Bevacizumab to Colombia

* Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top...

2025-10-27 20:30 890

BioDlink's Bevacizumab Approved for Market Launch in Indonesia, Marking Fourth Consecutive Emerging Market Authorization

* Bevacizumab Injection officially approved by Indonesia's National Agency of Drug and Food Contr...

2025-08-21 20:00 1471

BioDlink Accelerates Global Expansion with Bevacizumab Launch in Colombia and Pakistan

- BioDlink's bevacizumab injection secures marketing authorization in Colombia andPakistan followin...

2025-08-13 20:00 1724

BioDlink's Bevacizumab Approved for Market Launch in Nigeria, Accelerating Global Expansion

* BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National ...

2025-06-16 20:30 1656

BioDlink Strengthens Global Compliance with Argentina GMP Certification

* Global Milestone: GMP certification from Argentina, marking a key step in its global expansion ...

2025-06-05 20:30 1912

BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth

* International recognition of quality system with GMP-compliance in the key markets ofBrazil, In...

2025-05-21 20:30 2029

BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate

* BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212...

2025-05-08 20:30 4246

SUCCESSFUL PASSING OF EU QP AUDIT ON TOT BIOPHARM'S COMMERCIAL PRODUCTION BASE FOR MONOCLONAL ANTIBODY DRUG SUBSTANCES AND ANTIBODY DRUG CONJUGATES

SUZHOU,China, Oct. 27, 2022 /PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHAR...

2022-10-27 08:00 3264

Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares

SUZHOU, China, June 2, 2022 /PRNewswire/ -- On June 1, 2022, TOT BIOPHARM International Company Lim...

2022-06-02 08:00 6633

TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China

SUZHOU, China, Dec. 2, 2021 /PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHAR...

2021-12-02 08:00 3328

TOT BIOPHARM Anounces 2021 Interim Results

Revenue Surges 78% to RMB23.13 million CDMO Business Achieves Leapfrog Breakthrough Two Products App...

2021-08-13 10:59 20254